Treatment of Latent Tuberculosis Infection

Publication Date: February 14, 2020
Last Updated: March 14, 2022

Recommendations for regimens to treat latent tuberculosis infection

Having trouble viewing table?
Priority rank* Regimen Recommendation
(strong or conditional)
Evidence
(high, moderate, low, or very low)
Preferred 3 mos isoniazid plus rifapentine given once weekly Strong Moderate
Preferred 4 mos rifampin given daily Strong Moderate (HIV negative)
Preferred 3 mos isoniazid plus rifampin given daily Conditional Very low (HIV negative)
Conditional Low (HIV positive)
Alternative 6 mos isoniazid given daily Strong§ Moderate (HIV negative)
Conditional Moderate (HIV positive)
Alternative 9 mos isoniazid given daily Conditional Moderate
* Preferred: excellent tolerability and efficacy, shorter treatment duration, higher completion rates than longer regimens and therefore higher effectiveness; alternative: excellent efficacy but concerns regarding longer treatment duration, lower completion rates, and therefore lower effectiveness.
No evidence reported in HIV-positive persons.
§ Strong recommendation for those persons unable to take a preferred regimen (e.g., due to drug intolerability or drug-drug interactions).

Overview

Title

Treatment of Latent Tuberculosis Infection

Authoring Organization